21GRAMS, part of Real Chemistry and Janssen
Engineered for a Challenging Landscape: RYBREVANT® (amivantamab-vmjw) Takes on the Toughest EGFR Lung Cancers
We leveraged oncologist’s discomfort with exon 20 insertion mutations by talking about these cancers differently—characterizing them as a new type of tough EGFR-mutant disease when their go-to treatment can’t get the job done. This established the need for a new treatment, RYBREVANT®, to take on the toughest cancers.
21GRAMS, part of Real Chemistry Team Members:
Ericka McKenna, EVP, Group Account Director
Maria Colicchio, SVP, Group Account Director
Emily Dzilenski, Group Account Supervisor
Madeline Eldredge, Senior Account Executive
Claire Eckroate, VP, Group Account Director
Sarah Brown, Account Supervisor
Brian Petty, Associate Director, Project Management
Hayley Martini, Senior Project Manager
Maureen Alves, EVP, Head of Planning
Jessica Kumar, VP, Director of Medical Strategy
Leesa Wytock, EVP, Executive Director, Experience
Will Cruthers, Associate Director, Experience
Lauren Pollina, Executive Creative Director, Copy
Kristen Farina, VP, Creative Director, Copy
Sean Rowland, Copy Supervisor
Sierra Rea, Copy Supervisor
Chris Charles, Executive Creative Director, Art
Nathaniel Kuritz, VP, Creative Director, Art
Alex Peltzman, Associate Creative Director, Art
Alex Fabrizio, Group Art Supervisor
Margot Hayes, Senior Art Director
